RKDA
Arcadia Biosciences, Inc.
$1.03
-3.74%
$2.1M
No data for this timeframe.
Vol
Market Cap$2.1M
Cap SizeNano Cap
Inst. Holders8 funds
Inst. Value$53.6K
Inst. Activity0 buys / 1 sells
SEC Reports3
Press Releases3
Recent Activity
May 14, 2026
SEC
Arcadia Biosciences reported Q1 2026 revenue of $1.1M, down 8% YoY from $1.2M, and a net loss of $4.4M ($2.11/share) vs
8-K — Impact 6/10
Apr 30, 2026
SEC
Arcadia Biosciences filed Amendment No. 1 to its 2025 10-K solely to add Part III information (director/officer details,
10-K/A — Impact 5/10
Apr 3, 2026
SEC
Arcadia Biosciences (RKDA) dismissed Deloitte & Touche LLP as its independent auditor and appointed Ramirez Jimenez Inte
8-K — Impact 7/10
Inst.
MORGAN STANLEY — NEAR_EXIT
2 shares ($4.00)
Inst.
UBS Group AG — TRIM
1,099 shares ($3.8K)
Jun 13, 2026
Press
Arcadia Biosciences closed a private placement raising approximately $4 million in gross proceeds through the sale of co
Impact 7/10
Jun 13, 2026
offering
Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
<p>DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=r
Jun 12, 2026
Press
Arcadia Biosciences announces a private placement of ~3.88M common shares (or pre-funded warrants) plus two series of pr
Impact 7/10
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Aug 21, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 23, 2024 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Apr 5, 2024 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Aug 28, 2023 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Jul 24, 2023 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Latest Reports
BEARISH
Press
7/10
Arcadia Biosciences closed a private placement raising approximately $4 million in gross proceeds through the sale of co
Jun 13, 2026
BEARISH
8-K
6/10
Arcadia Biosciences reported Q1 2026 revenue of $1.1M, down 8% YoY from $1.2M, and a net loss of $4.4M ($2.11/share) vs
May 14, 2026
NEUTRAL
10-K/A
5/10
Arcadia Biosciences filed Amendment No. 1 to its 2025 10-K solely to add Part III information (director/officer details,
Apr 30, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $17.4K | — |
| STATE STREET CORP | $16.8K | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $13.3K | — |
| VANGUARD FIDUCIARY TRUST CO | $6.1K | — |
| GROUP ONE TRADING LLC | $25.00 | — |
8 institutional holders with $53.6K total value (38,824 shares) as of 2026-Q1. Top holders: SUSQUEHANNA, STATE, VANGUARD.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 12,614 | $17.4K | 32.5% | — |
| 2 | STATE STREET CORP | 12,146 | $16.8K | 31.3% | — |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 9,644 | $13.3K | 24.8% | — |
| 4 | VANGUARD FIDUCIARY TRUST CO | 4,394 | $6.1K | 11.3% | — |
| 5 | GROUP ONE TRADING LLC | 18 | $25.00 | 0.0% | — |
| 6 | ASSETMARK, INC | 5 | $7.00 | 0.0% | — |
| 7 | MORGAN STANLEY | 2 | $3.00 | 0.0% | NEAR_EXIT -99.7% |
| 8 | CITIGROUP INC | 1 | $1.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | NEAR_EXIT | 608 | 2 | -99.7% | $4.00 | 2025-Q4 |
| UBS Group AG | TRIM | 2,544 | 1,099 | -56.8% | $3.8K | 2025-Q3 |
| Mariner, LLC | TRIM | 27,481 | 14,500 | -47.2% | $62.5K | 2025-Q2 |
| UBS Group AG | TRIM | 8,560 | 2,544 | -70.3% | $11.0K | 2025-Q2 |
| UBS Group AG | TRIM | 13,945 | 8,560 | -38.6% | $25.4K | 2025-Q1 |
| UBS Group AG | DOUBLED | 239 | 13,945 | +5734.7% | $82.6K | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
3 SEC filing reports analyzed. Sentiment: 0 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 6.0/10.
BEARISH
8-K
6/10
Arcadia Biosciences reported Q1 2026 revenue of $1.1M, down 8% YoY from $1.2M, and a net loss of $4.
May 14, 2026
NEUTRAL
10-K/A
5/10
Arcadia Biosciences filed Amendment No. 1 to its 2025 10-K solely to add Part III information (direc
Apr 30, 2026
BEARISH
8-K
7/10
Arcadia Biosciences (RKDA) dismissed Deloitte & Touche LLP as its independent auditor and appointed
Apr 3, 2026
BEARISH
7/10
Arcadia Biosciences closed a private placement raising approximately $4 million in gross proceeds th
Jun 13, 2026
BEARISH
7/10
Arcadia Biosciences announces a private placement of ~3.88M common shares (or pre-funded warrants) p
Jun 12, 2026
MIXED
6/10
Arcadia Biosciences reported a 4% year-over-year decline in full-year 2025 revenue despite a 17% inc
Mar 26, 2026
Historical analyst distribution (last covering-analyst action Aug 2024): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2025-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY 2025-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Aug 21, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 23, 2024 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 5, 2024 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 28, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jul 24, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 5, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Apr 14, 2023 | HC Wainwright & Co. | MAINTAIN | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 13, 2026
offering
Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
<p>DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=rJ2Omqrf0zcudFtb0cnyd5Zbnrrii_krSEEq72irQjbNL9C9NF7
Jun 12, 2026
offering
Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
<p align="left">DALLAS, June 11, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=gYKFuu8mTbMSy3mjPAxHauRydS0mWEcHj5vYUB
Jun 11, 2026
short_volume
Short Volume: RKDA — 55.4% short (35.3M / 63.8M)
Short: 35,349,411 | Exempt: 447,991 | TRF Vol: 63,796,048 | Short Ratio: 55.4% | Off-exchange volume (dark pool + OTC)
May 6, 2026
earnings_calendar
RKDA Q1 2026 Earnings Scheduled — 2026-05-06
Mar 26, 2026
earnings
Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2025 Financial Results and Business Highlights
<p align="center"><strong><em>-- Zola</em></strong><sup><strong><em>®</em></strong></sup><strong><em> revenues increase 17% year-over-year --</em></st
Mar 18, 2026
earnings_calendar
RKDA Q4 2025 Earnings After Market Close — 2026-03-18